Carbetocin versus oxytocin in active management of third stage of labor: a randomized controlled trial
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20261256Keywords:
Carbetocin, Oxytocin, Postpartum hemorrhage, Third stage of labor, UterotonicsAbstract
Background: Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality. Active management of the third stage of labor (AMTSL) using uterotonic agents significantly reduces the incidence of PPH. Oxytocin is the most commonly used uterotonic; however, its short duration of action may necessitate repeated dosing. Carbetocin, a long-acting oxytocin analogue, offers sustained uterine contraction with a single dose.
Methods: A single-blind randomized controlled trial was conducted at a tertiary care center over 18 months. A total of 200 pregnant women with singleton or multiple pregnancies ≥32 weeks of gestation undergoing vaginal delivery or cesarean section were enrolled. Participants were randomly allocated into two groups: the carbetocin group (100 µg intravenous single dose) and the oxytocin group (10 IU intramuscular or 20 IU intravenous infusion). The primary outcomes assessed were blood loss within 24 hours postpartum, uterine tone, and requirement of additional uterotonics. Secondary outcomes included changes in hemoglobin levels, need for blood transfusion, hemodynamic changes, and drug-related adverse effects.
Results: Mean blood loss in the 1st 24 hours postpartum was significantly lower in the carbetocin group compared to the oxytocin group (398±138.52 ml versus 467±189.65 ml; p=0.004). Fewer women in the carbetocin group required additional uterotonic agents. Post-delivery hemoglobin levels were significantly higher in the carbetocin group. No significant adverse effects were observed in either group.
Conclusions: Carbetocin is more effective than oxytocin in reducing postpartum blood loss during active management of the third stage of labor, with the added advantage of single-dose administration and a comparable safety profile. Carbetocin can be considered a suitable alternative to oxytocin, particularly in tertiary care and high-risk obstetric settings.
References
World Health Organization. Trends in maternal mortality: 2000–2017. 2019. Available at: https://www.who.int/publications/i/item/9789241516488. Accessed on 15 February 2026.
Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams Obstetrics. 25th edition. New York: McGraw-Hill. 2018.
Sheldon WR, Blum J, Vogel JP, Souza JP, Gülmezoglu AM, Winikoff B. Postpartum hemorrhage management, risks, and maternal outcomes. Int J Gynaecol Obstet. 2014;127(2):109-15.
Begley CM, Gyte GM, Devane D, McGuire W, Weeks A, Biesty LM. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2019;2(2):CD007412.
World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012. Available at: https://www.who. int/publications/i/item/9789241548502. Accessed on 15 February 2026.
Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev. 2013;10:CD001808.
Güngördük K, Olgaç Y, Gülseren V, Kocaer M. Active management of the third stage of labor: A brief overview of key issues. Turk J Obstet Gynecol. 2018;15(3):188-92.
Arrowsmith S, Wray S, Quenby S. Oxytocin: mechanisms of action and receptor signalling. Obstet Gynecol. 2014;124(1):5-12.
Fuchs AR, Fuchs F. Oxytocin secretion and uterine sensitivity during pregnancy and parturition. Endocr Rev. 1984;5(1):30-47.
Torloni MR, Gomes Freitas C, Kartoglu UH, Gülmezoglu AM, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review. BJOG. 2016;123:2076-86.
Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin on the postpartum uterus. Obstet Gynecol. 1992;80(4):614-8.
Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;2:CD005457.
Attilakos G, Psaroudakis D, Ash J, Hayes L, Davey DA, Wray S, et al. Carbetocin versus oxytocin for prevention of postpartum haemorrhage. BJOG. 2010;117(8):929-36.
El Behery MM, El Sayed GA, El Hameed AA, Soliman BS. Carbetocin versus oxytocin in prevention of postpartum hemorrhage. J Obstet Gynaecol Res. 2015;41(9):1454-9.
Widmer M, Piaggio G, Abdel-Aleem H, Carroli G, Chong YS, Coomarasamy A, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage. N Engl J Med. 2018;379:743-52.
World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.
Attilakos G, Psaroudakis D, Ash J, Hayes L, Davey DA, Wray S, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section. BJOG. 2010;117(8):929-36.
El Behery MM, El Sayed GA, El Hameed AA, Soliman BS. Carbetocin versus oxytocin in prevention of postpartum hemorrhage. J Obstet Gynaecol Res. 2015;41(9):1454-9.
Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;2:CD005457.
Larciprete G, Montanari G, Valensise H, Facchinetti F, Di Renzo GC, Arduini D, et al. Carbetocin versus oxytocin-ergotamine infusion in the active management of the third stage of labor. Int J Gynaecol Obstet. 2007;99(2):110-5.
Arrowsmith S, Wray S, Quenby S. Oxytocin: mechanisms of action and receptor signalling. Obstet Gynecol. 2014;124(1):5-12.
Torloni MR, Gomes Freitas C, Kartoglu UH, Gülmezoglu AM. Quality of oxytocin available in low- and middle-income countries. BMJ Glob Health. 2016;1:e000042.
Downloads
Published
How to Cite
Issue
Section
